信必可都保装置.pptVIP

理想的吸入器(Idealhaler )? 易被患者接受 100% 肺内沉积率 剂量重复性好 剂量指示 体积小 奇特的 使用安全可靠 不依赖流速 对环境无污染 易用 耐潮湿 离散性好 多剂量 ………. 体外、体内和临床疗效的比较 不同病人使用都保时的吸气峰流速值(Peak Inhalation Flows, PIF) 幼儿可以有效使用都保? 严重COPD患者有效使用都保? 药物的肺部沉积率是临床疗效的重要决定因素 信必可?都保?肺部沉积率高于pMDI 信必可?都保?肺部沉积率高于准纳器? 研磨前布地奈德晶体 研磨后布地奈德微颗粒 微球化粉末 不同药品制剂 信必可?的药物输送更有效 信必可?使药物递送更有效 湿度的影响 湿度对稳定性的影响 信必可?都保?稳定性优于准纳器 信必可?都保?设计 信必可?都保?患者使用方便、简单 具有两项革新的、患者友好的特征 重新设计的吸嘴，更容易切合嘴部，患者使用更舒适 更具信息性的剂量计数器，提供剩余剂量的数字显示 即使在相对较低的吸气流速下(30L/min)也可获得有效的药物传输 都保? – 校验剂量 结论 微颗粒反映在肺内沉积上，肺内沉积反映在临床疗效上 都保肺内沉积优于准纳器和pMDI 准纳器对潮湿环境比较敏感, 都保在体内试验中较准纳器显示了更好的稳定性 信必可?都保 吸入粉剂:布地奈德和福莫特罗 剂型 80/4.5 mg 160/4.5 mg 适应症: 哮喘,适合使用联合方案治疗 (吸入糖皮质激素和长效b激动剂) 12岁及以上患者 每天两次1 - 2 吸入量 A process callled spheronisation can help. And after the milling the primary particles are spheronised to larger spheres. When it comes to the Symbicot formulation small lactoses particles are spheronised together with small particles of the two active drug components. Spheronisation is one way to solve the problem with the small particles. The other one is to use large lactose particles to carry the small particles of active drug. The lactose carrier particles are about 50 um large and the particles of active drug are 2-3 um. This is the traditional way and the way that most of our competitors have taken. When the small drug particles are mixed with the large lactose carrier particles the drug particles will adhere to energy rich sites on the lactose carrier particles. If more active drug is mixed with the same amount of lactose carrier this will result in a formulation with more loosely bound drug as the firstly covered energy rich sites will retain the active drug more firmly than other sites. The properties of the resulting formulation will depend on how much drug is loaded onto the carrier particles. In the co-spheronisation process the drug and lactose particles have the same size and thus we expect to see a homogenous mixture. This is the way AstraZeneca has chosen to go. These two different ways